Liver Cirrhosis: Pathophysiology and Biochemical Basis
- Dhanvin Raj Puppala
- 9 hours ago
- 4 min read
Introduction
Liver cirrhosis is the end stage of chronic liver injury characterized by diffuse fibrosis, regenerative nodule formation, and irreversible distortion of hepatic architecture. It develops secondary to chronic hepatic insults including alcohol-related liver disease, chronic viral hepatitis, metabolic dysfunction-associated steatotic liver disease (MASLD), autoimmune hepatitis, and inherited metabolic disorders. Progressve fibrosis disrupts normal hepatic blood flow and impairs the liver’s metabolic and synthetic functions.¹
The liver is one of the body’s most metabolically active organs. It regulates carbohydrate metabolism, lipid processing, protein synthesis, detoxification, bile production, and ammonia metabolism. Because of this central role, chronic liver injury affects multiple physiological systems simultaneously.²
Pathophysiology of Cirrhosis
A major event in the development of cirrhosis is activation of hepatic stellate cells (HSCs). Under normal conditions, these cells store vitamin A in the space of Disse. However, chronic hepatic injury activates these cells and transforms them into collagen-producing myofibroblast-like cells. Excessive extracellular matrix deposition, particularly type I and III collagen, progressively replaces healthy hepatic tissue, resulting in fibrosis and architectural distortion of the liver.²
As fibrosis progresses, hepatic blood flow becomes increasingly disrupted. This contributes to portal hypertension, impaired hepatocyte function, and reduced metabolic capacity of the liver.
Alcohol Metabolism and Liver Injury
Alcohol-associated liver disease remains one of the most common causes of cirrhosis worldwide. Ethanol metabolism occurs primarily through alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH):
Acetaldehyde, the intermediate metabolite, is highly toxic and contributes significantly to hepatocyte injury. It forms adducts with proteins and DNA, impairs mitochondrial function, and promotes inflammatory signaling pathways.³
Chronic alcohol metabolism also increases the hepatic NADH/NAD⁺ ratio, impairing β-oxidation of fatty acids while promoting triglyceride accumulation within hepatocytes. This contributes to hepatic steatosis, an early stage of alcohol-related liver disease.⁴
Oxidative Stress and Fibrogenesis
Oxidative stress plays a major role in progression toward cirrhosis. Chronic alcohol exposure induces cytochrome P450 2E1 (CYP2E1), leading to increased generation of reactive oxygen species (ROS), including superoxide radicals and hydrogen peroxide. ROS cause lipid peroxidation, mitochondrial injury, DNA damage, and hepatocyte apoptosis.⁵
Persistent oxidative stress also stimulates inflammatory cytokines such as transforming growth factor-beta (TGF-β), a key mediator of hepatic fibrogenesis. Continued inflammation and collagen deposition progressively worsen fibrosis and hepatic dysfunction.⁵
Metabolic Dysfunction and Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease has become an increasingly important cause of cirrhosis due to rising rates of obesity and type 2 diabetes mellitus. Insulin resistance increases peripheral lipolysis, resulting in elevated free fatty acid delivery to the liver. Excess lipid accumulation promotes steatosis, lipotoxicity, inflammation, and eventually steatohepatitis.⁶
Over time, chronic inflammatory injury may progress from simple steatosis to fibrosis and ultimately cirrhosis.
Portal Hypertension and Clinical Consequences
One of the major physiological consequences of cirrhosis is portal hypertension. Fibrotic distortion of hepatic sinusoids increases resistance to portal venous blood flow, elevating pressure within the portal circulation. This can lead to complications such as:
Ascites
Splenomegaly
Portosystemic shunting
Esophageal varices⁷
Reduced albumin synthesis further contributes to fluid accumulation by lowering plasma oncotic pressure.
Hepatic Encephalopathy and Ammonia Metabolism
Cirrhosis significantly impairs ammonia detoxification. Under normal physiological conditions, hepatocytes convert ammonia into urea through the urea cycle:
\text{Ammonia} \rightarrow \text{Urea}
In cirrhosis, impaired hepatocyte function and portosystemic shunting reduce ammonia clearance, resulting in hyperammonemia and hepatic encephalopathy. Elevated ammonia levels alter neurotransmission and promote astrocyte swelling through glutamine accumulation within the brain.⁸
Clinical manifestations include:
Confusion
Asterixis
Altered consciousness
Coma in severe cases⁸
Clinical Features
Patients with cirrhosis may initially remain asymptomatic due to the liver’s large functional reserve. As disease progresses, common clinical features include:
Fatigue
Jaundice
Ascites
Peripheral edema
Spider angiomas
Palmar erythema
Gynecomastia
Coagulopathy
Hepatic encephalopathy⁹
Advanced disease may ultimately progress to hepatocellular carcinoma or end-stage liver failure requiring transplantation.
Management and Prevention
Management focuses on slowing disease progression and treating complications. Important interventions include:
Alcohol cessation
Antiviral therapy for hepatitis
Weight reduction
Glycemic control
Nutritional optimization
Surveillance for complications¹⁰
Pharmacological management may involve diuretics for ascites, lactulose for hepatic encephalopathy, and non-selective beta blockers for portal hypertension. In advanced decompensated cirrhosis, liver transplantation remains the definitive treatment.¹⁰
Conclusion
Liver cirrhosis is a progressive pathological process involving chronic inflammation, oxidative stress, hepatocyte injury, and excessive fibrotic remodeling. Although multiple etiologies contribute to cirrhosis, the underlying biochemical pathways converge on hepatic stellate cell activation, extracellular matrix deposition, and disruption of normal hepatic function.
Understanding the biochemical basis of cirrhosis highlights the importance of early intervention, lifestyle modification, and prevention of chronic liver injury. With increasing global prevalence of obesity, alcohol misuse, and metabolic disease, cirrhosis remains a major public health challenge worldwide.
References
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-51.
Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125-72.
Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007;7(8):599-612.
Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc. 2004;63(1):49-63.
Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World J Gastroenterol. 2014;20(47):17756-72.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease. Hepatology. 2016;64(1):73-84.
Bosch J, Abraldes JG, Berzigotti A, García-Pagán JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6(10):573-82.
Butterworth RF. Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited. Metab Brain Dis. 2016;31(6):1211-5.
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-71.
Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398(10308):1359-76.
Image: Swiss Medica. Liver cirrhosis and stem cell treatment [Internet]. Belgrade: Swiss Medica; 2025 [cited 2026 May 6]. Available from: Swiss Medica Liver Cirrhosis Treatment
Assessed and Endorsed by the MedReport Medical Review Board
